SK281098B6 - Farmaceutický prostriedok na liečenie a/alebo prevenciu kostného úbytku s obsahom farmeceuticky účinného množstva alendronátu - Google Patents

Farmaceutický prostriedok na liečenie a/alebo prevenciu kostného úbytku s obsahom farmeceuticky účinného množstva alendronátu Download PDF

Info

Publication number
SK281098B6
SK281098B6 SK1477-96A SK147796A SK281098B6 SK 281098 B6 SK281098 B6 SK 281098B6 SK 147796 A SK147796 A SK 147796A SK 281098 B6 SK281098 B6 SK 281098B6
Authority
SK
Slovakia
Prior art keywords
pharmaceutical composition
alendronate
composition according
citric acid
sodium citrate
Prior art date
Application number
SK1477-96A
Other languages
English (en)
Slovak (sk)
Other versions
SK147796A3 (en
Inventor
Gerald S. Brenner
Ashok V. Katdare
Denise Pretzer
Donna T. Whiteford
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of SK147796A3 publication Critical patent/SK147796A3/sk
Publication of SK281098B6 publication Critical patent/SK281098B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1477-96A 1994-05-17 1995-05-12 Farmaceutický prostriedok na liečenie a/alebo prevenciu kostného úbytku s obsahom farmeceuticky účinného množstva alendronátu SK281098B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/245,289 US5462932A (en) 1994-05-17 1994-05-17 Oral liquid alendronate formulations
PCT/US1995/005926 WO1995031203A1 (en) 1994-05-17 1995-05-12 Oral liquid alendronate formulations

Publications (2)

Publication Number Publication Date
SK147796A3 SK147796A3 (en) 1997-07-09
SK281098B6 true SK281098B6 (sk) 2000-11-07

Family

ID=22926074

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1477-96A SK281098B6 (sk) 1994-05-17 1995-05-12 Farmaceutický prostriedok na liečenie a/alebo prevenciu kostného úbytku s obsahom farmeceuticky účinného množstva alendronátu

Country Status (34)

Country Link
US (1) US5462932A (fi)
EP (1) EP0759757B1 (fi)
JP (1) JP4111536B2 (fi)
KR (1) KR100372966B1 (fi)
CN (1) CN1079672C (fi)
AT (1) ATE222495T1 (fi)
AU (1) AU691634B2 (fi)
CA (1) CA2190148C (fi)
CO (1) CO4600739A1 (fi)
CY (1) CY2336B1 (fi)
CZ (1) CZ285860B6 (fi)
DE (1) DE69527842T2 (fi)
DK (1) DK0759757T3 (fi)
DZ (1) DZ1884A1 (fi)
ES (1) ES2180646T3 (fi)
FI (1) FI118296B (fi)
HK (1) HK1009245A1 (fi)
HR (1) HRP950293B1 (fi)
HU (1) HU220626B1 (fi)
IL (1) IL113651A (fi)
MX (1) MX9605660A (fi)
MY (1) MY112285A (fi)
NO (1) NO310179B1 (fi)
NZ (1) NZ289231A (fi)
PL (1) PL179634B1 (fi)
PT (1) PT759757E (fi)
RU (1) RU2176507C2 (fi)
SI (1) SI0759757T1 (fi)
SK (1) SK281098B6 (fi)
TW (1) TW402501B (fi)
UA (1) UA29505C2 (fi)
WO (1) WO1995031203A1 (fi)
YU (1) YU49354B (fi)
ZA (1) ZA953960B (fi)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
KR19980702210A (ko) * 1995-02-17 1998-07-15 폴락 돈나 엘 비척추골 골절의 위험률을 감소시키는 방법
JPH10506638A (ja) * 1995-05-12 1998-06-30 メルク エンド カンパニー インコーポレーテッド アレンドロネート又はその塩の投与による歯喪失の予防
IL118422A0 (en) * 1995-06-02 1996-09-12 Merck & Co Inc Use of alendronate for the prevention of osteoporosis
EP0831843A1 (en) * 1995-06-06 1998-04-01 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US6100301A (en) * 1996-02-28 2000-08-08 Pfizer Inc Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
PL332496A1 (en) * 1996-10-04 1999-09-13 Merck & Co Inc Liquid alendronate preparations
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
US6376476B1 (en) * 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
US6080779A (en) * 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
FI104901B (fi) 1997-10-20 2000-04-28 Leiras Oy Uudet metyleenibisfosfonihappojohdannaiset
GB9802617D0 (en) * 1998-02-07 1998-04-01 Knoll Ag Pharmaceutical formulation
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
US6194469B1 (en) * 1998-12-11 2001-02-27 Board Of Trustees Operating Michigan State Univeristy Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids
CA2376258A1 (en) * 1999-06-02 2000-12-14 The Procter & Gamble Company Oral preparations of etidronate disodium
US6677320B2 (en) 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
US6468559B1 (en) 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
AU7105501A (en) 2000-07-17 2002-01-30 Yamanouchi Pharma Co Ltd Pharmaceutical composition improved in peroral absorbability
BRPI0116865B8 (pt) * 2001-01-23 2021-05-25 Gador Sa composição compreendendo bisfosfonatos para prevenção e/ou tratamento de doenças metabólicas dos ossos, processo para preparar tal composição e uso desta
US7695535B2 (en) 2001-10-10 2010-04-13 River Basin Energy, Inc. Process for in-situ passivation of partially-dried coal
US8197561B2 (en) 2001-10-10 2012-06-12 River Basin Energy, Inc. Process for drying coal
US7537622B2 (en) * 2001-10-10 2009-05-26 Fmi Newcoal, Inc. Process for drying coal
JP2005516928A (ja) * 2001-12-13 2005-06-09 メルク　エンド　カムパニー　インコーポレーテッド 骨異常のためのビスホスホネート液体製剤
AU2002360619B2 (en) * 2001-12-21 2006-10-05 Allergan Pharmaceuticals International Limited Method for the treatment of bone disorders
CN100551377C (zh) 2002-05-10 2009-10-21 弗·哈夫曼-拉罗切有限公司 用于治疗和预防骨质疏松症的二膦酸
ITTO20020406A1 (it) * 2002-05-13 2003-11-13 Chiesi Farma Spa Formulazioni di bisfosfonati ad uso iniettabile.
US7041309B2 (en) * 2002-06-13 2006-05-09 Neuropro Technologies, Inc. Spinal fusion using an HMG-CoA reductase inhibitor
GR1004331B (el) * 2002-10-07 2003-09-05 Verisfield (Uk) Ltd Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος
PL212072B1 (pl) * 2002-12-20 2012-08-31 Hoffmann La Roche Tabletka zawierająca jako substancję czynną do 250 mg kwasu ibandronowego oraz sposób jej wytwarzania
US20050101605A1 (en) * 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
HUE059143T2 (hu) * 2004-05-24 2022-10-28 Theramex Hq Uk Ltd Kelátképzõ szert tartalmazó enterális szilárd orális biszfoszfonát dózisforma
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
CN1997374A (zh) * 2004-06-23 2007-07-11 默克公司 ***受体调节剂
EP1796683A1 (en) * 2004-07-15 2007-06-20 Nanobac Life Sciences Methods and compositions for the administration of calcium chelators, bisphosphonates and/or citrate compounds and their pharmaceutical uses
WO2006020009A1 (en) * 2004-07-23 2006-02-23 The Procter & Gamble Company Solid oral dosage form of a bisphosphonate containing a chelating agent
WO2008128056A1 (en) * 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
EP1802641B8 (en) * 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
WO2007095161A2 (en) * 2006-02-14 2007-08-23 New York University Methods and compositions for treating disorders associated with increased bone turnover and osteopenia
EP2001486A4 (en) * 2006-03-17 2010-12-29 Univ Illinois BIPHOSPHONATE COMPOUNDS AND CORRESPONDING METHODS
ATE498391T1 (de) * 2006-09-04 2011-03-15 Gador Sa Flüssige zusammensetzung für die behandlung und/oder verhinderung von verschiedenen metabolischen knochenkrankheiten, verwendung davon und vorbereitungsprozess.
KR20090083326A (ko) * 2006-11-21 2009-08-03 테이코쿠 팔마 유에스에이, 인코포레이티드 비스포스포네이트 흡입 제제와 그 사용 방법
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
US20090197837A1 (en) * 2008-02-05 2009-08-06 Desai Vivek S Alendronate formulations, method of making and method of use thereof
US20100034752A1 (en) * 2008-08-11 2010-02-11 Toru Hibi Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
US8956426B2 (en) 2010-04-20 2015-02-17 River Basin Energy, Inc. Method of drying biomass
US9057037B2 (en) 2010-04-20 2015-06-16 River Basin Energy, Inc. Post torrefaction biomass pelletization
US9889225B2 (en) * 2010-08-20 2018-02-13 Kaohsiung Medical University Method for bone formation by administering poly(lactic-co-glycolic acid) cross-linked alendronate
WO2012078528A2 (en) 2010-12-06 2012-06-14 Effrx Pharmaceuticals Sa Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
CN103070824B (zh) * 2013-01-24 2014-07-16 天津红日药业股份有限公司 一种含有伊班膦酸钠的注射液
JP2016532660A (ja) * 2013-10-08 2016-10-20 イノファーマ インク アプレピタント経口液体製剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
FI83421C (fi) * 1989-06-21 1991-07-10 Huhtamaeki Oy Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat.
US5227506A (en) * 1989-09-06 1993-07-13 Merck & Co., Inc. Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
CA2035179C (en) * 1990-01-31 2001-08-14 Gerald S. Brenner Pharmaceutical compositions containing insoluble salts of bisphosphonic acids
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .

Also Published As

Publication number Publication date
RU2176507C2 (ru) 2001-12-10
HU9603162D0 (en) 1997-01-28
HRP950293A2 (en) 1997-04-30
HK1009245A1 (en) 1999-05-28
CO4600739A1 (es) 1998-05-08
FI964593A0 (fi) 1996-11-15
DZ1884A1 (fr) 2002-02-17
ATE222495T1 (de) 2002-09-15
PL320614A1 (en) 1997-10-13
WO1995031203A1 (en) 1995-11-23
CY2336B1 (en) 2004-02-06
NZ289231A (en) 1998-04-27
CA2190148C (en) 2006-02-14
DE69527842T2 (de) 2003-04-10
UA29505C2 (uk) 2000-11-15
JP4111536B2 (ja) 2008-07-02
YU31795A (sh) 1999-06-15
MX9605660A (es) 1998-02-28
HUT76317A (en) 1997-08-28
CN1079672C (zh) 2002-02-27
TW402501B (en) 2000-08-21
DK0759757T3 (da) 2002-10-07
IL113651A (en) 1999-08-17
HU220626B1 (hu) 2002-03-28
CN1148341A (zh) 1997-04-23
PT759757E (pt) 2002-11-29
KR970703151A (ko) 1997-07-03
SI0759757T1 (en) 2002-12-31
PL179634B1 (pl) 2000-10-31
SK147796A3 (en) 1997-07-09
IL113651A0 (en) 1995-08-31
KR100372966B1 (ko) 2003-05-12
ES2180646T3 (es) 2003-02-16
FI118296B (fi) 2007-09-28
YU49354B (sh) 2005-09-19
CZ285860B6 (cs) 1999-11-17
AU2901095A (en) 1995-12-05
AU691634B2 (en) 1998-05-21
FI964593A (fi) 1996-11-15
ZA953960B (en) 1996-01-19
DE69527842D1 (de) 2002-09-26
MY112285A (en) 2001-05-31
NO310179B1 (no) 2001-06-05
HRP950293B1 (en) 2003-08-31
NO964864L (no) 1996-11-15
CZ336796A3 (en) 1997-06-11
US5462932A (en) 1995-10-31
EP0759757A1 (en) 1997-03-05
CA2190148A1 (en) 1995-11-23
JPH10504020A (ja) 1998-04-14
EP0759757B1 (en) 2002-08-21
NO964864D0 (no) 1996-11-15

Similar Documents

Publication Publication Date Title
SK281098B6 (sk) Farmaceutický prostriedok na liečenie a/alebo prevenciu kostného úbytku s obsahom farmeceuticky účinného množstva alendronátu
MXPA96005660A (en) Oral liquid formulations of alendron
US5843924A (en) Intravenous alendronate formulations
EP0524579B1 (en) Improved oral dosing formulations of dideoxy purine nucleosides
AU723357B2 (en) Liquid alendronate formulations
US7605148B2 (en) Aqueous oral solution of bisphosphonic acid
US6169083B1 (en) Preventives/remedies for stomatitis
CA2376258A1 (en) Oral preparations of etidronate disodium
US20090170815A1 (en) Alendronate oral liquid formulations
JPH0132804B2 (fi)
JPS63267727A (ja) Ｓ−ラクトイルグルタチオンおよび／またはその塩を有効成分とする医薬
AU719771B2 (en) Intravenous alendronate formulations
KR20000048829A (ko) 액체 알렌드로네이트 제형
JPH0840917A (ja) 向上した安全性側面を有する制酸薬調剤